CORE-008 Cohort B Tests Cretostimogene’s Efficacy in High-Risk, Non-BCG-Responsive Disease - Trinity Bivalacqua
Trinity Bivalacqua
Zachary Klaassen and Trinity Bivalacqua discuss Cohort B of the CORE-008 trial, which examines cretostimogene in BCG-exposed patients with high-risk non-muscle invasive bladder cancer.
